Schrödinger, Inc. (SDGR) reported a solid first quarter for 2026, with Annual Contract Value (ACV) reaching $28.4 million—up 12% year-over-year—driven by increased adoption among top pharmaceutical clients. Total revenue hit $58.6 million, with software revenue at $35.6 million and drug discovery revenue at $22.9 million. Notably, hosted software revenue surged to $12.1 million, accounting for 34% of total software revenue, reflecting a strategic shift towards hosted licensing models.
The financial results underscore a positive trend in the biopharmaceutical sector, as Schrödinger’s platform gains traction amidst a favorable funding environment. However, the company reported a net loss of $60 million, and software gross margins declined to 69% from 80%, attributed to the transition to hosted licensing. The recent $2.3 billion acquisition of Ajax Therapeutics by Eli Lilly, in which Schrödinger holds a 6% stake, is expected to provide a significant cash inflow, enhancing the company’s financial position.
Investors should note the ongoing shift to hosted licensing may create short-term revenue variability but positions Schrödinger for long-term growth and stability. The upcoming launch of Bunsen, an AI co-scientist, is anticipated to further enhance productivity and drive usage, potentially solidifying the company’s competitive edge in drug discovery.
Source: fool.com